Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 17/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.42 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837707 | 0.91 | TLR9 (0.42) | TLR9TLR8TLR7SMARCA2SMARCA4 | |
| SCHEMBL30178976 | 0.91 | TLR9 (0.42) | TLR9TLR8TLR7SMARCA2SMARCA4 | |
| SCHEMBL24461791 | 0.80 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1IKBKB | |
| SCHEMBL30552542 | 0.80 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1IKBKB | |
| SCHEMBL23581053 | 0.79 | SMARCA2 (0.51) | TLR9TLR8TLR7SMARCA2SMARCA4 | |
| SCHEMBL24838249 | 0.79 | IRAK4 (0.40) | TLR9TLR8TLR7 | |
| SCHEMBL30552632 | 0.78 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1IKBKB | |
| SCHEMBL30552600 | 0.78 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1IKBKB | |
| SCHEMBL24461569 | 0.78 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1IKBKB | |
| SCHEMBL24461482 | 0.77 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | TLR9 3834/4885TLR8 4561/4885QDPR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.